Maria I Carlo
Overview
Explore the profile of Maria I Carlo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
2422
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Latham A, Liu Y, Constantino G, Borio M, McCoy S, Dudzik C, et al.
Am J Gastroenterol
. 2025 Feb;
PMID: 40013688
Purpose: The age to initiate colonoscopy in MSH6/PMS2-associated Lynch Syndrome (LS) remains uncertain. Herein we characterize colonoscopy findings among young individuals with MSH6/PMS2-associated LS. Methods: Retrospective review of a multi-institutional...
2.
Makker S, Shah N, Carlo M, Kuo F, Hakimi A, Chen Y, et al.
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996894
Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare kidney tumor which is usually characterized by indolent disease physiology. While several high-grade and sarcomatoid MTSCC tumors have been reported,...
3.
Berg S, La Rosa S, Zhang T, Pierorazio P, Albiges L, Beckermann K, et al.
Urol Oncol
. 2024 Nov;
43(3):135-146.
PMID: 39500687
Modern advances in systemic and localized therapies for patients with renal cell carcinoma (RCC) have significantly improved patients' outcomes. If disease progression occurs after initial treatment, clinicians often have multiple...
4.
Fitzgerald K, Lee C, Voss M, Carlo M, Knezevic A, Peralta L, et al.
Eur Urol
. 2024 Oct;
87(1):96.
PMID: 39426859
No abstract available.
5.
Ma J, Del Balzo L, Walch H, Khaleel S, Knezevic A, Flynn J, et al.
Eur Urol Oncol
. 2024 Aug;
PMID: 39107179
Background: Molecular profiles of renal cell carcinoma (RCC) brain metastases (BMs) are not well characterized. Effective management with locoregional therapies, including stereotactic radiosurgery (SRS), is critical as systemic therapy advancements...
6.
Fitzgerald K, Lee C, Voss M, Carlo M, Knezevic A, Peralta L, et al.
Eur Urol
. 2024 May;
86(2):90-94.
PMID: 38782695
Treatment options are limited for patients with non-clear cell renal cell carcinoma (nccRCC). Patients with nccRCC experienced a favorable objective response rate (ORR) in a phase 2 trial of cabozantinib...
7.
Charbel C, Andrieu P, Soliman M, Woo S, Zheng J, Capanu M, et al.
Radiol Imaging Cancer
. 2024 Mar;
6(2):e230063.
PMID: 38456787
Purpose To investigate the prevalence of , and mutations in an oncologic cohort and determine the prevalence, clinical features, and imaging features of renal cell carcinoma (RCC) associated with these...
8.
Motzer R, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al.
J Natl Compr Canc Netw
. 2024 Feb;
22(1):4-16.
PMID: 38394781
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic...
9.
Reese S, Eismann L, White C, Villada J, Khaleel S, Ostrovnaya I, et al.
Urol Oncol
. 2023 Dec;
42(2):32.e9-32.e16.
PMID: 38135627
Purpose: The use of systemic immune checkpoint blockade before surgery is increasing in patients with metastatic renal cell carcinoma, however, the safety and feasibility of performing consolidative cytoreductive nephrectomy after...
10.
Kotecha R, Doshi S, Knezevic A, Chaim J, Chen Y, Jacobi R, et al.
Eur Urol Oncol
. 2023 Nov;
7(4):804-811.
PMID: 37945488
Background: Although different kidney cancers represent a heterogeneous group of malignancies, multiple subtypes including Von Hippel-Lindau (VHL)-altered clear cell renal cell carcinoma (ccRCC), fumarate hydratase (FH)- and succinate dehydrogenase (SDH)-deficient...